Roche
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry ten years in a row by the Dow Jones Sustainability Indices (DJSI). For more information, please visit https://careers.roche.com Read our community guidelines here: https://www.roche.com/some-guidelines.htm #Roche #Biotechnology #Pharmaceuticals #Diagnostics #Healthcare #PersonalisedHealthcare #GreatPlaceToWork #Innovation
read more
Details
Roche's efficiency score is not available. The company has raised a total of $7.8B. Learn about the Hidden Gem and Efficiency Scores.
Industries
Products
Technologies
Features
The following 0 companies are top matches based on Iterate's Proprietary algorithms.
Roche Highlights
Funding
$7.8B
±0
YoY
Headcount
91.9K
+5.9K
YoY
Patents
10
±0
YoY
News
99
4 Funding Rounds
Post-IPO Equity
$5B
2021-08-04
Investors
Unknown
Post-IPO Equity
$500K
2020-05-06
Investors
Unknown
Post-IPO Equity
2016-01-01
Investors
Unknown
Post-IPO Equity
$2.8B
2001-05-08
Investors
Unknown
Add Funding Round
No results found
Try your search again with different filters.